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CASE REPORT
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ABSTRACT
The myelodysplastic syndrome-myeloproliferative neoplasms (MDS/MPNs) are defined by a group of heterogeneous
hematological malignancies resulting from stem cell−driven clonal growth of pathological hematopoietic progenitors and
ineffective hematopoiesis, they are characterized concomitant myelodysplastic and myeloproliferative signs.
Myelodysplastic/myeloproliferative disorders have been considered to have a higher risk of thrombus formation.
We report a rare case about a 64 years old Moroccan woman, experienced renal infarction (RI) associated with pulmonary
embolism as a complication of a myelodysplastic/myeloproliferative disorder.
The patient complained of acute-onset severe left flank pain, a contrast-enhanced computed tomography (CT) of the chest
and abdomen revealed RI by a large wedge-shaped defect in the right kidney with pulmonary embolism.
The biological exam showed deep anemia, the bone marrow aspiration found myelodysplasia. the bone biopsy showed signs
of myeloproliferative disease. The karyotype was normal, BCR-ABL, JAK2, CALR mutations were absent, and MPL
mutation was positive. The International Prognostic Scoring System (IPSS-R) was 0, and the patient was included in the low
risk group.
Anticoagulation therapy was initiated with heparin to treat RI and pulmonary embolism. Three months later, pulmonary
embolism had resolved without the appearance of additional peripheral infarction.
This case emphasizes the need to consider myelodysplastic/myeloproliferative disorders as a cause of infraction renal and
pulmonary embolism.
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INTRODUCTION
syndrome-myeloproliferative
The
myelodysplastic
neoplasms (MDS/MPNs) are defined by a group of
heterogeneous hematological malignancies resulting from
stem cell−driven clonal growth of pathological
hematopoietic progenitors and ineffective hematopoiesis.
(1) They are characterized by bone marrow dysplasia and
cytopenia. They are also characterized by an increased
risk of development of secondary acute myeloid
leukemia. (2)
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The last revision of the WHO classification of myeloid
neoplasms and acute leukemia updated the MDS/MPN
category, on the new version (2016), MDS/MPN
syndromes include chronic myelomonocytic leukemia
(CMML), atypical chronic myelogenous leukemia
(aCML), juvenile myelomonocytic leukemia (JMML),
MDS/MPN with ringed sideroblasts and thrombocytosis
(MDS/MPN-RS-T), as well as unclassifiable forms of
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mixed myelodysplastic/myeloproliferative disorders
(MDS/MPN-U). (3)
Treatment is not proposed systematically for all patients,
asymptomatic patients are not treated initially, treatment
is reserved for symptomatic patients, such as those
requiring frequent blood transfusions. Prognosis and
overall survival depend upon multiple factors such as the
severity of cytopenias, the percentage of blasts in the
peripheral blood and bone marrow, and karyotype.
The International Prognostic Scoring System (IPSS-R) is
utilized to define life expectancy and leukemic
progression [4,5]. Transformation to acute myeloid
leukemia (AML) occurs in approximately 10% and 70%
of lower- and higher-risk (HR) patients, respectively. (6)
Myelodysplastic/myeloproliferative disorders have been
considered to have a higher risk of thrombus formation.
In this manuscript, we report the case of a 64-year-old
Moroccan
woman
suffering
from
myelodysplasic/myeloproliferative disorder with deep
thrombosis consisting on pulmonary embolism and renal
infarction.
CASE REPORT
We report a rare case about a 64 years old
postmenopausal Moroccan woman, without medical
history, was admitted to the emergency department with
acute-onset severe left flank pain with dyspnea which
started a week before admission.
The initial examination found a patient in good general
condition, Performance Status was at 2, a blood pressure
of 140/64 mmHg, and a heart rate of 85 beats per minute.
She was afebrile, with normal saturation. She had diffuse
abdominal tenderness, with splenomegaly (17cm).
Laboratory testing revealed anemia at 6.8g/dl, white
blood count at 8.9×103/L, absolute neutrophil count at
7.2× 103/L, absolute monocyte counts at 0.5×103/L
eosinophile count at 0.07×103/L, and lymphocytes count
at 1.03×103/L. Platelet count at 416 ×103/L and lactate
dehydrogenase at 145 IU / L.
Electrolytes, renal function, and liver function were
normal, albumin was 43 (32–45) g/L and urine analysis
was sterile.
CT scan of the chest and abdomen showed no signs of
pancreatitis or stones neither, evidence of ischemic bowel
or perforation was noted. It showed a focal area of
infarction in the right kidney with pulmonary embolism.
At first, we suspected the diagnosis of nephrolithiasis and
pyelonephritis, but the patient was afebrile and urine
analysis was normal, then the diagnosis of renal
infarction was retained, the Ultrasound for lower
extremity deep venous was normal.
The bone marrow aspiration showed normocellular
marrow and found a multiline dysplasia (more than 33%
of red cell precursors have signs of dysplasia,
granulocytic precursors have hyposegmentation and
hypersegmentation on 20% of cell) with blasts at 2%,
no ring sideroblasts by iron stains were found, Relevant
immunostains
were
performed
including
myeloperoxidase (MPO), CD34, CD117, CD61 for
megakaryocytes, CD68 for monocytes, CD20, and CD19
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for B-cell lineage and CD3 for T-cell lineage. The CD34,
is an antigen expressed on progenitor and early precursor
cells, which is a marker for blasts, it showed the absence
of blasts. New Generation Sequencing (NGS) was not
performed.
The bone marrow biopsy showed a myeloproliferative
syndrome type essential thrombocytemia. The karyotype
was normal, molecular biology showed the absence of
BCR-ABL rearrangement and JAK2 V617F (exon12) and
CALR mutations. The mutation in the MPL gene
(exon10) was positive.
According to WHO criteria, this patient was classified in
the category SMD / SMP unclassifiable. The
International Prognostic Scoring System (IPSS-R) was 0,
and the patient was included in the low risk group. No
treatment was indicated for the hematological disease.
The patient received anticoagulation therapy was initiated
with heparin to treat RI and pulmonary embolism. Three
months later, pulmonary embolism had resolved without
the appearance of additional peripheral infarction.
The patient was not overweight, she had no past medical
history of diabetes or high blood pressure, neither
hypercholesterolemia, she doesn’t smoke, the MDS/MNP
was considered as the unique origin of deep thrombosis
To date, the patient received a preventive dose of 10 mg
of Rivaroxaban per day continuously after six months of
treatment with heparin.
DISCUSSION
Myelodysplastic/ Myeloproliferative neoplasms are a rare
and heterogeneous hematologic neoplasm, the annual
incidence of MDS is more than 20 per 100,000 people.
(7) The median age of diagnosis is 71 to 76 years (2).
Patients suffering from MDS/MPN neoplasms can be
clinically asymptomatic for years and may have
incidental findings of cytopenias on routine labs. Others
may have complained about signs and symptoms related
to bone marrow failures such as fatigue, bleeding, or
infections. (8) the particularity of this entity is the
association between MDS signs and MPN features:
MDS-like features consist of cytopenias and dysplasia of
various cell lines while MPN-like features can be
traduced by constitutional symptoms (e.g. night sweats
and/or weight loss), elevated blood counts as well as
extramedullary infiltration.
The underlying pathogenesis responsible for this group of
neoplasms remains unclear as does the molecular
convergence point that biologically defines the
MDS/MPN category.
Transformation to acute myeloid leukemia (AML) occurs
in approximately 10% and 70% of lower- and higher-risk
(HR) patients, respectively. (6)
The last revision of the WHO classification of myeloid
neoplasms and acute leukemia updated the MDS/MPN
category, on the new version (2016), MDS/MPN
syndromes include chronic myelomonocytic leukemia
(CMML), atypical chronic myelogenous leukemia
BCR/ABL-negative (aCML), juvenile myelomonocytic
leukemia (JMML), MDS/MPN with ringed sideroblasts
and thrombocytosis (MDS/MPN-RS-T), as well as

2

Bendari M et al.

RI and PE in Patient with MDS/MPN Unclassifiable

unclassifiable
forms
of
mixed
myelodysplastic/myeloproliferative
disorders
(MDS/MPN-U). (3)
The prognosis for patients with MDS/MPN disorder is
heterogeneous; depending on the number of cytopenia,
presence of blasts, severity, and type of cytogenetic
defect. Karyotype with a good prognosis includes normal
karyotype, -Y, deletion 5q, deletion 20q. Poor risk
karyotypes include complex cytogenetics (greater than
three abnormalities), or chromosome 7 abnormalities. All
other karyotypes are categorized as intermediate risk.
Based on these findings, a score is calculated to
determine a risk score of either low, intermediate-1 or
intermediate-2, or high risk. (9)
The International Prognostic Scoring System (IPSS-R) is
utilized to define life expectancy and leukemic
progression. [4,5] It includes the degree of pancytopenia,
cytogenetic abnormalities, and some blasts. The early
stage, also known as very low-risk and low-risk MDS, is
characterized by low IPSS-R scores. Intermediate-, high-,
and very high-risk MDS patients have high IPSS-R
scores with profound pancytopenia, unfavorable
cytogenetic abnormalities, and increased blast count.
More than 100 genes have been identified to be
recurrently mutated in MDS, and these encode
spliceosome components, chromatin remodeling factors,
epigenetic pattern modulators, and transcription factors
among others. (10) The identification of the major
genetic pathways implicated in their pathogenesis not
only will help in their diagnosis, but also will enable the
development of targeted molecular therapy as well as
prognostic markers.
MDS/MPN disorders are considered as a high risk factor
of thrombosis. Arterial or venous thrombosis can appear
at the beginning of the disease and thus constitute a
telltale sign or occur later and become a complication of
the disease
Renal infarction (RI) results of sudden disruption of
blood flow in the renal arteries, and rapid diagnosis and
treatment are critical to prevent permanent loss of renal
function. (11)
RI is an underdiagnosed and
underreported phenomenon, it is often mistaken for renal
colic. The differential diagnoses are nephrolithiasis and
pyelonephritis, the presence of hematuria and elevated
lactate dehydrogenase should raise the suspicion of this
diagnosis.
For our patient, elevated lactate dehydrogenase was
elevated, but the diagnosis was initially suspected
because of the concomitant presence of pulmonary
embolism.
To the best of our knowledge, and according to the
literature, the risk factors of thromboembolic RI, other
than atrial fibrillation, include valvular or ischemic heart

disease, endocarditis, hypercoagulation disorders, and
hematological diseases. (11)
Clinical manifestations of RI are not specific. Patients
with acute renal infarction typically complain of acute
onset of flank pain, frequently accompanied by fever,
nausea, and vomiting. Oliguria is less common. (12-14)
Our patient was admitted with sudden onset of abdominal
pain radiating to the back we suspected at the first time
nephrolithiasis and pyelonephritis, but a radiological
exam confirms the concomitant presence of pulmonary
embolism and renal infarction.
The investigation confirmed the origin of deep
thrombosis,
and
the
diagnosis
of
myelodysplastic/myeloproliferative
neoplasm,
unclassifiable was retained. The majority of treatment
recommendations are extrapolated from clinical trials
focused on MDS or MPN patients and thus include very
few overlap syndrome patients. Current treatment options
for patients with MDS include conventional
chemotherapy
regimens,
chemotherapy
with
hypomethylating agents, and allogeneic hematopoietic
stem cell transplantation (HSCT). The therapeutic
strategy depends on many factors: age, IPSS-R score,
number of blasts, karyotype, and comorbidities. (15)
Prognosis and overall survival depend upon multiple
factors such as the severity of cytopenias, the percentage
of blasts in the peripheral blood and bone marrow, and
karyotype. The IPSS-R score of the patient was at 0, and
she was included to low risk group. On the other hand,
the treatment of RI must be treated because of the risk of
complete loss of renal function. Our patient received a
curative dose of heparin. Two months later, pulmonary
embolism had resolved without the appearance of
additional peripheral infarction.
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CONCLUSION
Myelodysplastic/myeloproliferative
neoplasm,
unclassifiable represents a heterogeneous group of rare
myeloid neoplasia with myeloproliferative and
myelodysplastic characteristics which requires vigilance
from the hematologist, their diagnostic and therapeutic
management is complicated.
We report an unusual case of renal infraction with
pulmonary
embolism
secondary
of
Myelodysplastic/myeloproliferative
neoplasm,
unclassifiable. This case emphasizes the need to consider
Myelodysplastic/myeloproliferative
neoplasm,
unclassifiable as a cause of RI, pulmonary embolism and
remind that the RI is an easily missed disease due to its
nonspecific presentation, and insist that early diagnosis
and early curative anticoagulation are the key to rapid
recovery but also preventive with long-term
antithrombotic prophylaxis.
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